Zimmer Biomet Files Preliminary Prospectus Supplement for Euro-Denominated Notes Offering

Offering Overview

On November 5, 2026, Zimmer Biomet Holdings, Inc. filed a preliminary prospectus supplement on Form 424B5 covering an offering of Euro-denominated senior unsecured notes.

Key Terms of the Notes

• Issuer: Zimmer Biomet Holdings, Inc.
• Security: Senior Notes denominated in Euro (€)
• Denomination: Minimum denominations of €100,000 and integral multiples of €1,000 in excess thereof.
• Ranking: Unsecured and unsubordinated obligations ranking equally with all existing and future senior unsecured debt and structurally subordinated to subsidiary debt. As of September 30, 2026, Zimmer Biomet reported approximately $7.5 billion of consolidated indebtedness (with no subsidiary debt).
• Optional Redemption: Redeemable at make-whole redemption prices prior to a specified par call date, and at 100% of principal plus accrued interest thereafter.
• Change of Control: Holders have the right to require repurchase at 101% of principal plus accrued interest upon a Change of Control Repurchase Event.
• Listing: The company will use reasonable efforts to list the notes on the New York Stock Exchange.

Use of Proceeds

Net proceeds are designated for general corporate purposes, which may include:

• Repayment of existing debt obligations (including portions of its 2026 and/or 2027 notes)
• Share repurchases
• Capital expenditure commitments
• Financing future acquisitions

Underwriting Syndicate

The joint book-running managers for the offering are Barclays, Citigroup, HSBC, Morgan Stanley, and RBC Capital Markets.